LongevityBiz Newsletter 6
Wednesday, September 23, 2026
Market signals
Artificial intelligence (AI) sorts billions of DNA changes (Google DeepMind). AlphaGenome predicts which changes could disrupt gene activity, helping researchers choose experiments and drug targets.
Patient-derived cells show encouraging bone changes (University of Murcia team). The ten-woman pilot reported higher bone density and fewer fragility fractures, an early result for a potential regenerative treatment.
One medicine lowers two blood fats (Arrowhead). Early company-reported cholesterol and triglyceride reductions give developers a dual-target approach to mixed lipid disorders.
A new medicine targets spinal muscular atrophy (SMA) muscle weakness (Scholar Rock). ISEMBYLD adds muscle-directed treatment to existing nerve-focused care, creating a second treatment opportunity.
An exoskeleton helps with household tasks (Lifeward). Twelve people with paraplegia used powered assistance at home, giving rehabilitation providers a practical assessment and training use case.
1. AlphaGenome helps scientists find the DNA changes that matter
A prediction for every possible DNA-letter change
Google DeepMind’s AlphaGenome Atlas—a genomic research resource, separate from the LongevityBiz Atlas—launched September 8 with predictions for more than nine billion possible DNA changes. The number comes from roughly three billion positions in the human genome, each with three alternative DNA letters—not nine billion people or experiments. The AI learned from human and mouse experiments connecting DNA sequences with measured gene activity. It compares predicted activity before and after a letter changes.
From a predicted error to a laboratory finding
Scientists can prioritize changes likely to disrupt how cells work. In one example, a Broad Institute team identified an overlooked change in the DNM1 gene; AlphaGenome predicted faulty RNA splicing—the assembly of a gene's message—and laboratory screens confirmed that effect. That shows how a prediction can lead to a testable discovery. It does not establish that every prediction is right.
A shorter search for drug targets
Drug developers could use the map to narrow their search for disease mechanisms and treatment targets. Its potential lies in making an enormous search manageable; valuable products still depend on confirming the biology and showing that intervening helps patients.
Commercial access and further validation
Watch for commercial release of Google DeepMind’s AlphaGenome Atlas and further laboratory validation of its predictions.
Using Google DeepMind’s AlphaGenome Atlas
Google DeepMind’s AlphaGenome Atlas website and software interface are available for noncommercial research. The separate AlphaGenome base model is already commercially available through Google Cloud. Google DeepMind’s AlphaGenome Atlas is a research resource, not an approved clinical test.
2. Bone-targeted cells show early signs of repair in osteoporosis
Giving a patient’s cells a route to bone
A September 11 Cell paper reports a first-in-human study in ten women with advanced osteoporosis. Researchers collected each woman's bone-marrow-derived mesenchymal cells and temporarily changed sugars on the cell surface to help the cells home to bone. Each participant then received one intravenous infusion. This was temporary surface editing, not permanent gene editing.
Encouraging signs of bone repair
Regenerative cells cannot help much if too few reach the tissue that needs them. The study tests a practical idea: give the cells a temporary molecular “address” for bone. Researchers reported increased markers of bone formation, more bone tissue, higher bone density by volume, and fewer fragility fractures during follow-up, with no serious adverse events. These are encouraging signs of bone repair, not proof of osteoporosis reversal. With no untreated comparison group, the study cannot show that the infusion caused the changes.
A delivery method worth developing
If later controlled studies confirm that cell-surface editing reliably improves tissue targeting, delivery could become a product capability of its own—built internally, partnered for, or licensed. Any commercial opportunity still depends on reproducible manufacturing, consistent cells, controlled efficacy evidence, and clear rights. The paper discloses related intellectual-property interests.
A controlled trial is the next test
The next meaningful evidence would be a larger controlled trial that can separate treatment effects from the natural course of disease and other care.
No patient treatment or enrollment route yet
The registered study is completed. Researchers can contact the authors through the paper, but there is no verified enrollment path or commercially available treatment for patients.
3. Arrowhead’s experimental medicine lowers cholesterol and triglycerides
Two blood fats fall after one dose
Arrowhead reported early human results on September 15 for ARO-DIMER-PA: after single doses, LDL (low-density lipoprotein) cholesterol, often called “bad” cholesterol, fell by a mean maximum of 54% and triglycerides by 73%. The experimental medicine uses RNA interference to reduce the messages that tell liver cells to make two proteins involved in controlling cholesterol and triglycerides. It quiets protein production rather than editing DNA.
Lower blood fats are the first step
LDL cholesterol and triglycerides are different blood fats. The two targeted proteins affect how the body handles them, so one medicine could address both. These are early, company-reported laboratory results, not evidence of fewer heart attacks or longer life. The announcement does not disclose the analyzed participant count, and the findings have not been peer reviewed.
One medicine with two jobs
The development opportunity is a medicine with two complementary jobs. If the effect lasts and safety is acceptable, one medicine could offer another way to treat mixed lipid disorders. That possibility needs evidence; it is not yet a demonstrated advantage over existing medicines.
Durability and safety come next
Watch for full participant-level results, repeat-dose safety and durability, and eventual cardiovascular outcomes.
Where the trial is recruiting
The Phase I/IIa trial lists recruiting sites in Australia, Canada, Georgia, and New Zealand. Trial participation is the available route, not an approved treatment.
4. ISEMBYLD gives people with SMA a second way to improve movement
A muscle treatment alongside nerve-focused care
The FDA approved ISEMBYLD, or apitegromab-mstn, for people aged two and older with spinal muscular atrophy who already receive an SMN2-targeted treatment, which helps a backup gene produce more of the protein their nerve cells need. SMA is a genetic disease in which too little survival motor neuron protein leads to the loss of motor neurons—the nerve cells that control movement—and then progressive muscle weakness and wasting. ISEMBYLD is an intravenous infusion given every four weeks that blocks activation of myostatin, a protein that restrains skeletal-muscle growth.
More children achieved motor improvement
ISEMBYLD adds a second approach aimed directly at muscle. In the principal analysis of 156 children aged two to 12 who could not walk independently, 34.2% of those receiving ISEMBYLD 10 mg/kg achieved clinically meaningful motor improvement at one year, compared with 13.5% receiving placebo.
Treating the weakness that other care leaves behind
Treating the cause of a disease does not always restore strength. Scholar Rock has built an additional medicine for that remaining need, potentially expanding what an existing treatment program can achieve. ISEMBYLD is not approved for age-related muscle loss or healthy aging, and the main efficacy analysis was pediatric.
Longer-term movement and fracture results
Watch for longer-term evidence on motor improvement and fracture risk.
Start with an SMA specialist
Patients start with an SMA specialist. Scholar Rock Supports offers insurance and infusion coordination, while local availability still requires confirmation. FDA reports an increased risk of fractures, including serious fractures, and warns that ISEMBYLD may cause fetal harm and may affect reproductive function. Those risks belong in the specialist treatment decision.
5. ReWalk helps people with paraplegia do more at home
Standing for tasks in the home
A peer-reviewed observational study, published September 1, followed 12 people with paraplegia due to chronic spinal-cord injury while they used personal exoskeletons—powered wearable frames that assist standing and walking—at home. All 12 completed kitchen tasks while standing, and ten completed grooming tasks. Participants also reported better performance and satisfaction after home use.
More everyday options, with assistance
For someone who normally uses a wheelchair, standing for food preparation or grooming can expand everyday options. Participants still needed a companion, and some found the device difficult to maneuver. The small observational study shows assisted tasks, not recovery from spinal-cord injury.
Training makes the hardware useful
For rehabilitation providers, the opportunity is not just selling hardware. It is building assessment and training around tasks a person values, then deciding whether the device adds a useful option to that person's mobility plan. The small study makes that service model tangible, but broader adoption depends on who can use the device safely, how much support training requires, and whether payers cover it.
Which benefits last beyond the pilot?
Larger studies could show which household tasks benefit most, how much help users need, and whether those gains last.
Arrange a ReWalk evaluation
Lifeward's ReWalk Personal product page provides an evaluation and training route. Eligible users need training and a specially certified companion for specified home and community use. Pricing is not public, and reimbursement assistance cannot guarantee coverage.
What these advances make possible
These technologies begin at different stages, but each tackles the same practical problem: getting an intervention closer to the place where it can be useful. AlphaGenome directs experiments toward higher-priority DNA changes. Surface-edited cells aim for bone. ARO-DIMER-PA sends two silencing functions to the liver. ISEMBYLD acts on muscle after nerve-focused SMA treatment. ReWalk supports selected tasks in the home.
Their evidence and access are not interchangeable. AlphaGenome is a research resource; the bone-cell approach and ARO-DIMER-PA remain investigational; ISEMBYLD has a narrow FDA-approved use; and ReWalk has an evaluation and training pathway. The opportunity is to turn those capabilities into something people can use: stronger bones and muscles, better control of blood fats, and more choices in daily life.
GLP-1 watch
Adding a second medicine lifts early weight-loss results
Lilly reported Phase 1 weight loss of 17% over 16 weeks with eloralintide 3 mg plus tirzepatide 5 mg, versus 10% with tirzepatide 5 mg alone, in adults with obesity or overweight. The calculation assumes participants stayed on treatment without adding other prohibited weight-loss treatments. Eloralintide targets amylin, another hormone pathway involved in fullness. Developers are testing whether adding that pathway can improve on GLP-1-based treatment alone. These company-announced early results do not establish long-term benefit or safety; the combination remains investigational. Phase 2 results in adults also living with type 2 diabetes are due September 30.
More from LongevityBiz
You're reading Newsletter 6. Catch up on earlier issues, compare companies in the LongevityBiz Atlas, or explore Rick Polito's reporting.
The LongevityBiz Atlas compares company offerings, customers, pricing, and business models. Free subscribers can explore LongevityBiz Atlas 150 at no charge through October 31, 2026, using their LongevityBiz subscription email.
Rick's Deep Dive 6: Naturopaths find good fit in longevity industry. Read his reporting in the Deep Dive library; subscriber access is free through October 31, 2026.